pd-l1

By Targets:	PD-1/PD-L1 (165) 5-HT Receptor (1) Adrenergic Receptor (1) Akt (1) Apoptosis (13) Aryl Hydrocarbon Receptor (2) Autophagy (3) Bcr-Abl (1) c-Fms (1) c-Kit (2) CTLA-4 (2) Cytochrome P450 (4) DGK (2) Discoidin Domain Receptor (2) Dopamine Receptor (1) Drug-Linker Conjugates for ADC (1) E3 Ligase Ligand-Linker Conjugates (2) EGFR (1) ERK (1) Eukaryotic Initiation Factor (eIF) (1) FAK (1) FLT3 (2) Fungal (3) GPR55 (1) HBV (1) HDAC (4) HIF/HIF Prolyl-Hydroxylase (2) Histone Demethylase (2) HSP (3) IFNAR (1) IKK (1) Integrin (1) Interleukin Related (1) Isotope-Labeled Compounds (1) JNK (1) Keap1-Nrf2 (1) LAG-3 (3) Ligands for Target Protein for PROTAC (2) LRRK2 (3) MAP4K (3) MNK (2) Monoamine Oxidase (6) Neurotensin Receptor (1) NF-κB (1) Phosphatase (2) Phosphodiesterase (PDE) (1) PROTAC Linkers (3) PROTACs (3) Reactive Oxygen Species (3) Src (1) STAT (4) STING (3) Target Protein Ligand-Linker Conjugates (2) TGF-β Receptor (1) TNF Receptor (1) Toll-like Receptor (TLR) (6) Trk Receptor (2) ULK (1) VEGFR (3) α-synuclein (3)
By Research Areas:	Cancer (188) Cardiovascular Disease (1) Endocrinology (1) Infection (10) Inflammation/Immunology (53) Neurological Disease (14)
Click Chemistry:	Azide (1)

Targets Recommended: PD-1/PD-L1

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-149830

PD-L1-IN-2	PD-1/PD-L1	Cancer
PD-L1-IN-2 is a potential tumor immunological agent by inhibiting *PD-L1. PD-L1-IN-2 is a Naamidine J derivative and exerts antitumor effects in vivo by reducing PD-L1* expression and enhancing tumor-infiltrating T-cell immunity. PD-L1-IN-2 is used for colorectal cancer research ^[1].

HY-139781

PD-L1-IN-1	PD-1/PD-L1	Cancer
PD-L1-IN-1 is a potent *PD-L1* inhibitor with an IC₅₀ of 115 nM. PD-L1-IN-1 strongly binds with the PD-L1 protein and challenged it in a co-culture of PD-L1 expressing cancer cells (PC9 and HCC827 cells) and peripheral blood mononuclear cells enhanced antitumor immune activity of the latter. PD-L1-IN-1 significantly increased interferon γ release and apoptotic induction of cancer cells, with low cytotoxicity in healthy cells ^[1].

HY-162356

PD-L1-IN-4	PD-1/PD-L1	Cancer
PD-L1-IN-4 (Compound X18) is an orally active *PD-L1* inhibitor that exhibits remarkable inhibitory activity against the PD-1/PD-L1 interaction (IC₅₀ = 1.3 nM) and enhances PD-L1 inhibitory effect on T cells (EC₅₀ = 152.8 nM). PD-L1-IN-4 can be used for the research of cancer ^[1].

HY-155101

PD-L1-IN-3	PD-1/PD-L1	Cancer
PD-L1-IN-3 (Compound 4a) is a compound that targets PD-1/PD-L1, the IC₅₀ value and EC₅₀ value is 4.97nM and 2.70 μM for inhibit *PD-L1* and Jurkat T cells, respectively. PD-L1-IN-3 can bind PD-L1 dimer to prevent PD-1 binding to PD-L1, therefore blocking PD-1 signaling. PD-L1-IN-3 can be used for lung cancer and melanoma diseases research ^[1].

HY-162357

PD-L1-IN-5

PD-1/PD-L1 Cancer

PD-L1-IN-5 (X22) is an orally active PD-L1 inhibitor, with the IC₅₀ value of 785.6 nM. PD-L1-IN-5 has anti-tumor activity in vivo ^[1].

PD-L1-IN-5	PD-1/PD-L1	Cancer
PD-L1-IN-5 (X22) is an orally active *PD-L1* inhibitor, with the IC₅₀ value of 785.6 nM. PD-L1-IN-5 has anti-tumor activity in vivo ^[1].

HY-162399

PD-L1-IN-6	PD-1/PD-L1 STAT	Inflammation/Immunology
PD-L1-IN-6 (Compound 16) is an orally active inhibitor for *PD-L1* expression in neutrophil by targeting STAT3 with K_D of 90.5 nmol/L. PD-L1-IN-6 promotes neutrophil-mediated antifungal immunoresponse ^[1].

HY-160585

PD-L1/PD-1-IN-1	PD-1/PD-L1	Inflammation/Immunology Cancer
PD-L1/PD-1-IN-1 (compound 8j) is a potent inhibitor of *PD-L1/PD* interaction, with IC₅₀ ＜ 1 nM. PD-L1/PD-1-IN-1 plays an important role in anti-tumor research ^[1].

HY-P2478

*Human PD-L1* inhibitor V**	PD-1/PD-L1	Inflammation/Immunology
Human PD-L1 inhibitor V, a *human PD-1* protein binding peptide with a K_d** value of 3.32 μM. Human PD-L1 inhibitor V inhibit the interaction of hPD-1/hPD-L1 ^[1].

HY-P2474

*Human PD-L1* inhibitor I**	PD-1/PD-L1	Cancer
Human PD-L1 inhibitor I is a *hPD-1* peptide ligand, with a K_D of 3.39 μM. Human PD-L1 inhibitor I may disturb the binding of hPD-L1 to hPD-1 ^[1].

HY-P2478A

*Human PD-L1* inhibitor V TFA**	PD-1/PD-L1	Inflammation/Immunology
Human PD-L1 inhibitor V TFA, a *human PD-1* protein binding peptide with a K_d** value of 3.32 μM. Human PD-L1 inhibitor V TFA inhibit the interaction of hPD-1/hPD-L1 ^[1].

HY-P2564

Human PD-L1 inhibitor III

PD-1/PD-L1 Inflammation/Immunology Cancer

Human PD-L1 inhibitor III is a human PD-L1 inhibitor.
HY-P2470

Human PD-L1 inhibitor II

PD-1/PD-L1 Cancer

Human PD-L1 inhibitor II is a potent PD-L1 inhibitor with anti-cancer activity ^[1].

*Human PD-L1* inhibitor III**	PD-1/PD-L1	Inflammation/Immunology Cancer
Human PD-L1 inhibitor III is a human PD-L1 inhibitor.

*Human PD-L1* inhibitor II**	PD-1/PD-L1	Cancer
Human PD-L1 inhibitor II is a potent *PD-L1* inhibitor with anti-cancer activity ^[1].

HY-P2477

*Human PD-L1* inhibitor IV**	PD-1/PD-L1	Inflammation/Immunology
Human PD-L1 inhibitor IV, a polypeptide, is a competitive *human PD-1* protein inhibitor with a K_d** value of 1.38 μM. Human PD-L1 inhibitor IV inhibits the interaction of hPD-1/hPD-L1 ^[1].

HY-P5276

Human membrane-bound PD-L1 polypeptide

PD-1/PD-L1 Cancer

Human membrane-bound PD-L1 polypeptide can be used as an antigen to induce PD-L1 antibody production ^[1].

*Human membrane-bound PD-L1* polypeptide**	PD-1/PD-L1	Cancer
Human membrane-bound PD-L1 polypeptide can be used as an antigen to induce *PD-L1* antibody production ^[1].

HY-157811

*PD-1/PD-L1-IN-40*	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-40 (Compound EP16) is a *PD-1/PD-L1* inhibitor. PD-1/PD-L1-IN-40 inhibits the generation of exosomal PD-L1 with IC₅₀ = 0.108 μM. PD-1/PD-L1-IN-40 can serve as a leading compound for exosomal PD-L1 abrogation. PD-1/PD-L1-IN-40 can be used for the research of cancer ^[1].

HY-134884

INCB086550 pd-1/pd-l1-IN-8	PD-1/PD-L1	Cancer
INCB086550 is a potent, oral, small-molecule *PD-L1* inhibitor with IC_50s value of 3.1, 4.9 and 1.9 nM for human, cynomolgus, and rat, respectively. INCB086550 promotes the dimerization of cell-surface PD-L1 and induces PD-L1 entry into Golgi vesicles then traffick to the nucleus. INCB086550 can be used for multiple cancers research ^[1].

HY-145774

*PD-1/PD-L1-IN-23*	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-23 is a potent and orally active inhibitor of *PD-1/PD-L1. PD-1/PD-L1-IN-23 is an ester proagent of L7. L7 is a benzo[c][1,2,5]oxadiazole derivative and biologically evaluated as inhibitors of PD-L1. PD-1/PD-L1-IN-23 displays significant antitumor effects in tumor models of syngeneic and PD-L1* humanized mice ^[1].

HY-154869

*PD-1/PD-L1-IN-34*	PD-1/PD-L1	Inflammation/Immunology Cancer
PD-1/PD-L1-IN-34 (Compound (1S,2S)-A25) inhibits *PD-1/PD-L1* interaction (IC₅₀=0.029 μM), with a selected binding affinity with PD-L1 (K_D=0.1554 μM). PD-1/PD-L1-IN-34 inhibits tumor growth by activating the immune microenvironment ^[1].

HY-152240

*PD-1/PD-L1-IN-29*	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-29 (S4-1) is a potent *PD-1/PD-L1* inhibitor with an IC₅₀ value of 6.1 nM. PD-1/PD-L1-IN-29 binds PD-L1 and disrupts PD-1/PD-L1 interactions, induces PD-L1 dimerization and internalization, improves its localization to the endoplasmic reticulum, and promotes PD-L1 entry into the endoplasmic reticulum. PD-1/PD-L1-IN-29 has anticancer activity ^[1].

HY-162343

PD-1/PD-L1-IN-41

PD-1/PD-L1 Inflammation/Immunology Cancer

PD-1/ PD-L1-in-41 (Compound 5c) is a PD-L1 and PD-1 inhibitor with IC₅₀ value of 10.2 nM ^[1].

*PD-1/PD-L1-IN-41*	PD-1/PD-L1	Inflammation/Immunology Cancer
PD-1/ PD-L1-in-41 (Compound 5c) is a *PD-L1* and *PD-1* inhibitor with IC₅₀ value of 10.2 nM ^[1].

HY-103048

*PD-1/PD-L1-IN 3*	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN 3, a macrocyclic peptide, is a potent and selective inhibitor of the *PD-1/PD-L1* and *CD80/PD-L1* interactions extracted from patent WO2014151634A1, compound No.1. PD-1/PD-L1-IN 3 interferes with PD-L1 binding to PD-1 and CD80 by binding to PD-L1, with IC₅₀s of 5.60 nM and 7.04 nM, respectively. PD-1/PD-L1-IN 3 can be used for the research of various diseases, including cancer and infectious diseases ^[1].

HY-103048A

*PD-1/PD-L1-IN 3 TFA*	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN 3 TFA, a macrocyclic peptide, is a potent and selective inhibitor of the *PD-1/PD-L1* and *CD80/PD-L1* interactions extracted from patent WO2014151634A1, compound No.1. PD-1/PD-L1-IN 3 TFA interferes with PD-L1 binding to PD-1 and CD80 by binding to PD-L1, with IC₅₀s of 5.60 nM and 7.04 nM, respectively. PD-1/PD-L1-IN 3 TFA can be used for the research of various diseases, including cancer and infectious diseases ^[1].

HY-144258

*PD-1/PD-L1-IN-14*	PD-1/PD-L1	Inflammation/Immunology Cancer
PD-1/PD-L1-IN-14 (compound 17) is a bifunctional inhibitor of *PD-1/PD-L1* interactions, with an IC₅₀ of 27.8 nM. PD-1/PD-L1-IN-14 (compound 17) inhibits PD-1/PD-L1 interactions and promotes dimerization, internalization, and degradation of PD-L1 ^[1].

HY-163307

*PD-1/PD-L1-IN-39*	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-39 (X 14) is an orally active *PD-1/PD-L1* inhibitor with a IC₅₀ value of 15.73 nM. PD-1/ PD-L1-in-39 has a good binding affinity for human and mouse PD-L1, with K_D values of 14.62 nM and 392 nM, respectively. PD-1/PD-L1-IN-39 has antitumor activity ^[1].

HY-158052

*PD-1/PD-L1* antagonist 1**	PD-1/PD-L1	Cancer
PD-1/PD-L1 antagonist 1 (Compound A5) is an antagonist for programmed cell death-1 (PD-1) and programmed cell death ligand-1 (PD-L1) interaction, with an IC₅₀ of 23.78 nM ^[1].

HY-144447

*PD-1/PD-L1-IN-17*	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-17 (Compound P20) is a potent inhibitor of *PD-1/PD-L1* with an IC₅₀ value of 26.8 nM. PD-1/PD-L1-IN-17 is a promising lead compound for the development of inhibitors of the PD-1/PD-L1 interaction. PD-1/PD-L1-IN-17 has the potential for the research of cancer diseases ^[1].

HY-155959

*PD-1/PD-L1-IN-33*	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-33 (Compound N11) is a *PD-1/PD-L1* inhibitor. PD-1/PD-L1-IN-33 inhibits PD-1 and PD-L1 interaction with an IC₅₀: 6.3 nM. PD-1/PD-L1-IN-33 promotes T-cell proliferation, activation, and infiltration into tumor spheres. PD-1/PD-L1-IN-33 has immunomodulatory and anticancer activity ^[1].

HY-144442

*PD-1/PD-L1-IN-15*	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-15 (Compound M17) is a potent inhibitor of *PD-1/PD-L1* with an IC₅₀ value of 60.1 nM. PD-1/PD-L1-IN-15 has the potential for the research of tumor immunoresearch ^[1].

HY-144443

*PD-1/PD-L1-IN-16*	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-16 (Compound M23) is a potent inhibitor of *PD-1/PD-L1* with an IC₅₀ value of 53.2 nM. PD-1/PD-L1-IN-16 has the potential for the research of tumor immunoresearch ^[1].

HY-132192

*PD-1/PD-L1-IN-9*	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-9 is a potent and orally active inhibitor of *PD-1/PD-L1* interaction, with an IC₅₀ of 3.8 nM. PD-1/PD-L1-IN-9 can enhance the killing activity of tumor cells by immune cells. PD-1/PD-L1-IN-9 also exhibits significant in vivo antitumor activity in a CT26 mouse model ^[1].

HY-132192A

*PD-1/PD-L1-IN-9 hydrochloride*	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-9 hydrochloride is a potent and orally active inhibitor of *PD-1/PD-L1* interaction, with an IC₅₀ of 3.8 nM. PD-1/PD-L1-IN-9 hydrochloride can enhance the killing activity of tumor cells by immune cells. PD-1/PD-L1-IN-9 hydrochloride also exhibits significant in vivo antitumor activity in a CT26 mouse model ^[1].

HY-116274

BMS-8	PD-1/PD-L1	Cancer
BMS-8 inhibits the *PD-1/PD-L1* interaction with IC₅₀ of 7.2 μM. BMS-8, binds directly to PD-L1 and induces formation of PD-L1 homodimers, which in turn prevents the interaction with PD-1 ^[1].

HY-144746

*PD-1/PD-L1-IN-26*	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-26 (Compound II-14) is a potent inhibitor of *PD-1/PD-L1* with an IC₅₀ of 0.0380 μM. PD-1/PD-L1-IN-26 activates the immune microenvironment by promoting the infiltration of CD4+ T cells into tumor tissues. PD-1/PD-L1-IN-26 has the potential for the research of cancer diseases ^[1].

HY-129172

*PD-1/PD-L1-IN 5 TFA*	PD-1/PD-L1	Infection Inflammation/Immunology Cancer
PD-1/PD-L1-IN 5 TFA is a *PD-1/PD-L1* protein/protein interaction inhibitor extracted from patent WO2017222976A1, compound Example 1, has an IC₅₀ of ≤100 nM ^[1].

HY-153064

MAX-10181 pd-1/pd-l1-IN-30	PD-1/PD-L1	Cancer
MAX-10181 (PD-1/PD-L1-IN-30) is a *PD-1/PD-L1* binding inhibitor, with an IC₅₀ value of 0.018 μM. MAX-10181 can be used for research of cancers and other related diseases ^[1].

HY-P99145

Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2)

PD-1/PD-L1 Inflammation/Immunology

Anti-Mouse PD-L1/B7-H1 Antibody is an anti-mouse PD-L1 IgG2b antibody inhibitor derived from host rat.

*Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2)*	PD-1/PD-L1	Inflammation/Immunology
Anti-Mouse PD-L1/B7-H1 Antibody is an anti-mouse *PD-L1* IgG2b antibody inhibitor derived from host rat.

HY-131183

*PROTAC PD-1/PD-L1* degrader-1**	PROTACs PD-1/PD-L1	Inflammation/Immunology
PROTAC PD-1/PD-L1 degrader-1, a *PD-1/PD-L1* PROTAC based on Cereblon E3 ligand, inhibits PD-1/PD-L1 interaction with an IC₅₀ of 39.2 nM. PROTAC PD-1/PD-L1 degrader-1 significantly restores the immunity repressed in a co-culture model of Hep3B/OS-8/hPD-L1 and CD3 T cells. PROTAC PD-1/PD-L1 degrader-1 moderately reduces the protein levels of PD-L1 in a lysosome-dependent manner ^[1].

HY-156150

*CYP51/PD-L1-IN-2*	Fungal Cytochrome P450 PD-1/PD-L1	Infection
CYP51/PD-L1-IN-2 (compound L20) is a quinazoline compound with antifungal activity. CYP51/PD-L1-IN-2 is a dual inhibitor of CYP51 (IC₅₀: 0.263 μM) and PD-L1 (IC₅₀: 0.017 μM), which can induce early apoptosis of fungal cells in the cell cycle. CYP51/PD-L1-IN-2 also significantly reduced intracellular IL-2, NLRP3, and NF-κBp65 protein levels, induced mitochondrial damage and ROS accumulation, and ultimately led to fungal lysis and death ^[1].

HY-156151

*CYP51/PD-L1-IN-3*	Fungal Cytochrome P450 PD-1/PD-L1	Infection
CYP51/PD-L1-IN-3 (compound L21) is a quinazoline compound with antifungal activity. CYP51/PD-L1-IN-3 is a dual inhibitor of CYP51 (IC₅₀: 0.205 μM) and PD-L1 (IC₅₀: 0.039 μM), which can induce early apoptosis of fungal cells in the cell cycle. CYP51/PD-L1-IN-3 also significantly reduced intracellular IL-2, NLRP3, and NF-κBp65 protein levels, induced mitochondrial damage and ROS accumulation, and ultimately led to fungal lysis and death ^[1].

HY-156149

*CYP51/PD-L1-IN-1*	Fungal Cytochrome P450 PD-1/PD-L1	Infection
CYP51/PD-L1-IN-1 (compound L11) is a quinazoline compound with antifungal activity. CYP51/PD-L1-IN-1 is a dual inhibitor of CYP51 (IC₅₀: 0.884 μM) and PD-L1 (IC₅₀: 0.083 μM), which can induce early apoptosis of fungal cells in the cell cycle. CYP51/PD-L1-IN-1 also significantly reduced intracellular IL-2, NLRP3, and NF-κBp65 protein levels, induced mitochondrial damage and ROS accumulation, and ultimately led to fungal lysis and death ^[1].

HY-138407

Evixapodlin GS-4224; pd-1/pd-l1-IN 7	PD-1/PD-L1 HBV	Infection Cancer
Evixapodlin (GS-4224) is a *human PD-1/PD-L1* protein/protein interaction inhibitor with an IC₅₀** of 0.213 nM. Evixapodlin has anticancer and antiviral functions ^[1].

HY-P99633

Garivulimab BGB-A333	PD-1/PD-L1 Apoptosis	Cancer
Garivulimab (BGB-A333) is a humanized IgG1-variant monoclonal antibody that specifically targets and binds to *PD-L1. Garivulimab selectively blocks the interaction of PD-L1* and PD-1. Garivulimab has antitumor activity ^[1].

HY-P99833

Cosibelimab CK-301; TG-1501	PD-1/PD-L1	Cancer
Cosibelimab (CK-301; TG-1501) is a high-affinity, fully human *PD-L1*-blocking monoclonal antibody that binds PD-L1 and blocks its interaction with PD-1. Cosibelimab has a functional Fc domain and is capable of inducing ADCC and complement-dependent cytotoxicity (CDC)-mediated killing of PD-L1 ⁺ cell lines, including lymphoma cells ^[1].

HY-P99944

SHR-1701

Retlirafusp alfa
PD-1/PD-L1 TGF-β Receptor Cancer

SHR-1701 (Retlirafusp alfa) is a bifunctional fusion protein targeting PD-L1 and TGF-β for cancer research ^[1].

SHR-1701 Retlirafusp alfa	PD-1/PD-L1 TGF-β Receptor	Cancer
SHR-1701 (Retlirafusp alfa) is a bifunctional fusion protein targeting *PD-L1* and TGF-β for cancer research ^[1].

HY-19745

BMS-202 10+ Cited Publications	PD-1/PD-L1 Apoptosis	Cancer
BMS-202 is a potent and nonpeptidic PD-1/PD-L1 complex inhibitor with an IC₅₀ of 18 nM and a K_D of 8 μM. BMS-202 binds to PD-L1 and blocks human PD-1/PD-L1 interaction. BMS-202 has antitumor activity ^[1] .

HY-120402

BMS-200

PD-1/PD-L1 Inflammation/Immunology

BMS-200 is a potent PD-1/PD-L1 interaction inhibitor with an IC₅₀ of 80 nM. BMS-200 can induce dimerization of PD-L1 ^[1].

BMS-200	PD-1/PD-L1	Inflammation/Immunology
BMS-200 is a potent PD-1/PD-L1 interaction inhibitor with an IC₅₀ of 80 nM. BMS-200 can induce dimerization of PD-L1 ^[1].

HY-150879

BMS-37	PD-1/PD-L1 Ligands for Target Protein for PROTAC	Cancer
BMS-37 is a *PD-1/PD-L1* immune checkpoint inhibitor. BMS-37 can be used as PD-L1 ligand to synthesize PROTAC molecules ^[1].

HY-108730

Avelumab 5+ Cited Publications Anti-Human pd-l1, Human Antibody; MSB 0010718C; MSB0010718C	PD-1/PD-L1	Inflammation/Immunology Cancer
Avelumab is a fully human IgG1 anti-PD-L1 monoclonal antibody with potential antibody-dependent cell-mediated cytotoxicity.

HY-P99544

Tagitanlimab HBM-9167; KL-A167	PD-1/PD-L1	Cancer
Tagitanlimab (HBM-9167) is a *humanized anti-PD-L1* antibody (IgG1κ type). Tagitanlimab selectively blocks the interaction of PD-L1 and PD-1**. Tagitanlimab has the potential to be studied in recurrent or metastatic nasopharyngeal carcinoma (NPC) ^[1] .

HY-N12687

Benzosceptrin C	PD-1/PD-L1 Apoptosis	Cancer
Benzosceptrin C is an inhibitor for *PD-L1, which promotes programmed cell death ligand (PD-L1*) degradation in a lysosomal pathway, enhances the cytotoxicity of T-cells and exhibits antitumor activity ^[1].

Cat. No.	Product Name

HY-L031

Small Molecule Immuno-Oncology Compound Library

486 compounds

Immuno-Oncology is a type of immunotherapy that has the specific purpose of treating cancer. It works by stimulating our immune system to fight back. Normally, our immune system is able to destroy cancer cells in our body, however sometimes cancer cells can adapt and mutate, effectively hiding from our immune system. This is when tumors can develop and become a threat to our health. Immuno-oncology involves mobilizing lymphocytes to recognize and eliminate cancer cells using the body’s immune system. There are several immuno-oncology treatments available, including Immune cell therapy (CAR-T), monoclonal antibodies (mABs) and checkpoint inhibitors, cytokines and cancer vaccines.

MCE Small Molecule Immuno-Oncology Compound Library offers 486 bioactive tumor immunology compounds that target some important checkpoints such as PD1/PD-L1, CXCR, Sting, IDO, TLR, etc. This library is a useful tool for Immuno-oncology research.

HY-L079

Anti-Blood Cancer Compound Library

2676 compounds

Blood cancers, also called hematologic cancers, occur when abnormal blood cells start growing out of control, interrupting the function of normal blood cells, which fight off infection and produce new blood cells. Most blood cancers start in the bone marrow, which is where blood is produced. There are three main types of blood cancers: leukemia, lymphoma and myeloma, which afflict millions of children and adults every year, and are often deadly.

Some common blood cancer treatments include stem cell transplantation, chemotherapy, radiation therapy, targeted therapy, immunotherapy or a combination thereof. As we begin to understand the key signaling pathways and molecular drivers of malignant transformation in haematological disorders, new treatment strategies will continue to be developed.

MCE offers a unique collection of 2676 compounds with identified and potential anti-blood cancer activity. These compounds target blood cancer’s major targets and signaling pathways. MCE anti-blood cancer compound library is a useful tool for anti-blood cancer drugs screening and other related research.

HY-L007

Immunology/Inflammation Compound Library

5006 compounds

The immune system is a host defense system comprising many biological structures and processes within an organism that protects against disease. To function properly, an immune system must detect a wide variety of agents, known as pathogens, from viruses to parasitic worms, and distinguish them from the organism's own healthy tissue. Inflammation is also the body's attempt at self-protection to remove harmful stimuli and begin the healing process. It’s part of the body's immune response. The immune system recognizes damaged cells, irritants, and pathogens, and inflammation begins the healing process. Inflammatory abnormalities are a large group of disorders that underlie a vast variety of human diseases. The immune system is often involved with inflammatory disorders, demonstrated in both allergic reactions and some myopathies, with many immune system disorders resulting in abnormal inflammation.

MCE designs a unique collection of 5006 compounds that are useful tool for Immunology/Inflammation research or autoimmune inflammatory diseases drug discovery.

HY-L109

Protein-protein Interaction Inhibitor Library

576 compounds

Protein protein interactions (PPI) have pivotal roles in life processes. The studies showed that aberrant PPI are associated with various diseases, including cancer, infectious diseases, and neurodegenerative diseases. The classic drug targets are usually enzymes, ion channels, or receptors, the PPI indicate new potential therapeutic targets. Therefore, targeting PPI is a new direction in treating diseases and an essential strategy for the development of new drugs.

However, the design of modulators targeting PPI still faces tremendous challenges, such the difficult PPI interfaces for the drug design, lack of ligands reference, lack of guidance rules for the PPI modulators development and high-resolution PPI proteins structures.

With the development of high-throughput technology, high-throughput screening is also gradually used for the identification of PPI inhibitors, but the compound library used for conventional target screening is not very effective in screening PPI inhibitors. To improve screening efficiency, MCE carefully selected 576 PPI inhibitors and mainly targeting MDM2-p53, Keap1-Nrf2, PD-1/PD-L1, Myc-Max, etc. MCE Protein-protein Interaction Inhibitor Library is a useful tool for PPI drug discovery and related research.

Cat. No.	Product Name	Target	Research Area

HY-P2478

*Human PD-L1* inhibitor V**	PD-1/PD-L1	Inflammation/Immunology
Human PD-L1 inhibitor V, a *human PD-1* protein binding peptide with a K_d** value of 3.32 μM. Human PD-L1 inhibitor V inhibit the interaction of hPD-1/hPD-L1 ^[1].

HY-P2474

*Human PD-L1* inhibitor I**	PD-1/PD-L1	Cancer
Human PD-L1 inhibitor I is a *hPD-1* peptide ligand, with a K_D of 3.39 μM. Human PD-L1 inhibitor I may disturb the binding of hPD-L1 to hPD-1 ^[1].

HY-P2470

Human PD-L1 inhibitor II

PD-1/PD-L1 Cancer

Human PD-L1 inhibitor II is a potent PD-L1 inhibitor with anti-cancer activity ^[1].

HY-P2478A

*Human PD-L1* inhibitor V TFA**	PD-1/PD-L1	Inflammation/Immunology
Human PD-L1 inhibitor V TFA, a *human PD-1* protein binding peptide with a K_d** value of 3.32 μM. Human PD-L1 inhibitor V TFA inhibit the interaction of hPD-1/hPD-L1 ^[1].

HY-P2564

Human PD-L1 inhibitor III

PD-1/PD-L1 Inflammation/Immunology Cancer

Human PD-L1 inhibitor III is a human PD-L1 inhibitor.

HY-P2477

*Human PD-L1* inhibitor IV**	PD-1/PD-L1	Inflammation/Immunology
Human PD-L1 inhibitor IV, a polypeptide, is a competitive *human PD-1* protein inhibitor with a K_d** value of 1.38 μM. Human PD-L1 inhibitor IV inhibits the interaction of hPD-1/hPD-L1 ^[1].

HY-P5276

Human membrane-bound PD-L1 polypeptide

PD-1/PD-L1 Cancer

Human membrane-bound PD-L1 polypeptide can be used as an antigen to induce PD-L1 antibody production ^[1].

HY-103048A

*PD-1/PD-L1-IN 3 TFA*	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN 3 TFA, a macrocyclic peptide, is a potent and selective inhibitor of the *PD-1/PD-L1* and *CD80/PD-L1* interactions extracted from patent WO2014151634A1, compound No.1. PD-1/PD-L1-IN 3 TFA interferes with PD-L1 binding to PD-1 and CD80 by binding to PD-L1, with IC₅₀s of 5.60 nM and 7.04 nM, respectively. PD-1/PD-L1-IN 3 TFA can be used for the research of various diseases, including cancer and infectious diseases ^[1].

HY-P1812

AUNP-12 NP-12	PD-1/PD-L1	Cancer
AUNP-12 (NP-12) is a peptide antagonist of the PD-1 signaling pathway, displays equipotent antagonism toward PD-L1 and PD-L2 in rescue of lymphocyte proliferation and effector functions. AUNP-12 exhibits immune activation, excellent antitumor activity, and potential for better management of immune-related adverse events (irAEs) ^[1].

HY-P1812A

AUNP-12 TFA NP-12 TFA	PD-1/PD-L1	Cancer
AUNP-12 TFA (NP-12 TFA) is a peptide antagonist of the PD-1 signaling pathway, displays equipotent antagonism toward PD-L1 and PD-L2 in rescue of lymphocyte proliferation and effector functions. AUNP-12 TFA exhibits immune activation, excellent antitumor activity, and potential for better management of immune-related adverse events (irAEs) ^[1].

HY-P3440

WL12	PD-1/PD-L1	Cancer
WL12 is a specifically targeting programmed death ligand 1 (PD-L1) binding peptide. WL12 can be radiolabeled by different radionuclides, generating radiotracers, which can assess the tumor PD-L1 expression ^[1].

HY-P3139

TPP-1	PD-1/PD-L1	Cancer
TPP-1 is a potent inhibitor of the PD-1/PD-L1 interaction. TPP-1 binds specifically to PD-L1 with a high affinity (K_D=95 nM). TPP-1 inhibits human tumor growth in vivo via reactivating T-cell function ^[1].

HY-P3139A

TPP-1 TFA	PD-1/PD-L1	Cancer
TPP-1 TFA is a potent inhibitor of the PD-1/PD-L1 interaction. TPP-1 TFA binds specifically to PD-L1 with a high affinity (K_D=95 nM). TPP-1 TFA inhibits human tumor growth in vivo via reactivating T-cell function ^[1].

HY-P3143A

BMSpep-57 hydrochloride	PD-1/PD-L1	Cancer
BMSpep-57 hydrochloride is a potent and competitive macrocyclic peptide inhibitor of PD-1/PD-L1 interaction with an IC₅₀ of 7.68 nM. BMSpep-57 hydrochloride binds to PD-L1 with K_ds of 19 nM and 19.88 nM in MST and SPR assays, respectively. BMSpep-57 hydrochloride facilitates T cell function by in creasing IL-2 production in PBMCs ^[1].

HY-P3143

BMSpep-57	PD-1/PD-L1	Cancer
BMSpep-57 is a potent and competitive macrocyclic peptide inhibitor of PD-1/PD-L1 interaction with an IC₅₀ of 7.68 nM. BMSpep-57 binds to PD-L1 with K_ds of 19 nM and 19.88 nM in MST and SPR assays, respectively. BMSpep-57 facilitates T cell function by in creasing IL-2 production in PBMCs ^[1].

HY-P4072

(D)-PPA 1	PD-1/PD-L1	Cancer
(D)-PPA 1 is a hydrolysisresistant d-peptide antagonist. (D)-PPA 1 serves as a potent *PD-1/PD-L1* inhibitor. (D)-PPA 1 binds to PD-1 with the affinity 0f 0.51 μM with in vitro and in vivo efficacy ^[1].

HY-P4072A

(D)-PPA 1 TFA	PD-1/PD-L1	Cancer
(D)-PPA 1 TFA is a hydrolysisresistant d-peptide antagonist. (D)-PPA 1 TFA serves as a potent *PD-1/PD-L1* inhibitor. (D)-PPA 1 TFA binds to PD-1 with the affinity 0f 0.51 μM with in vitro and in vivo efficacy ^[1].

HY-P5041

α-Synuclein (34-45) (human)	α-synuclein	Neurological Disease
α-Synuclein (34-45) (human) is the 34-45 fragment of α-Synuclein. α-Synuclein is an abundant neuronal protein that is highly abundant in presynaptic nerve terminals. α-Synuclein is a Parkinson's disease (PD) biomarker .

HY-P3342

[D-Leu-4]-OB3	PD-1/PD-L1 Apoptosis	Inflammation/Immunology
[D-Leu-4]-OB3 inhibits expressions of pro-inflammatory, proliferative and metastatic genes and PD-L1* expression.* [D-Leu-4]-OB3 stimulates expression of pro-apoptotic genes ^[1].

HY-149941

hNTS1R agonist-1	Neurotensin Receptor	Neurological Disease
hNTS1R agonist-1 (Compound 10) is a BBB permeable *hNTS1R* full agonist (K_i: 6.9 nM) . hNTS1R agonist-1 increases motor function and memory in a mouse model of Parkinson's disease (PD). hNTS1R agonist-1 is a Neurotensin(8-13) analog and is a neuroprotective agent ^[1].

HY-P10091

CD24/Siglec-10 blocking peptide, CSBP	PD-1/PD-L1	Cancer
CD24/Siglec-10 blocking peptide, CSBP can not only block the interaction of CD24/Siglec-10 but also PD-1/PD-L1. CD24/Siglec-10 blocking peptide, CSBP can induce the phagocytosis of tumor cell ^[1].

Cat. No.	Product Name	Target	Research Area

HY-P99145

Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2)

PD-1/PD-L1 Inflammation/Immunology

Anti-Mouse PD-L1/B7-H1 Antibody is an anti-mouse PD-L1 IgG2b antibody inhibitor derived from host rat.

HY-P99833

Cosibelimab CK-301; TG-1501	PD-1/PD-L1	Cancer
Cosibelimab (CK-301; TG-1501) is a high-affinity, fully human *PD-L1*-blocking monoclonal antibody that binds PD-L1 and blocks its interaction with PD-1. Cosibelimab has a functional Fc domain and is capable of inducing ADCC and complement-dependent cytotoxicity (CDC)-mediated killing of PD-L1 ⁺ cell lines, including lymphoma cells ^[1].

HY-P990173

*Anti-Mouse/Rat/Human PD-L1* Antibody (368A.4H1)**	Inhibitory Antibodies	Others
Anti-Mouse/Rat/Human PD-L1 Antibody (368A.4H1) is a mouse-derived IgG1, κ type antibody inhibitor, targeting to mouse/rat/human PD-L1.

HY-P99633

Garivulimab BGB-A333	PD-1/PD-L1 Apoptosis	Cancer
Garivulimab (BGB-A333) is a humanized IgG1-variant monoclonal antibody that specifically targets and binds to *PD-L1. Garivulimab selectively blocks the interaction of PD-L1* and PD-1. Garivulimab has antitumor activity ^[1].

HY-P99944

SHR-1701

Retlirafusp alfa
PD-1/PD-L1 TGF-β Receptor Cancer

SHR-1701 (Retlirafusp alfa) is a bifunctional fusion protein targeting PD-L1 and TGF-β for cancer research ^[1].

HY-108730

Avelumab 5+ Cited Publications Anti-Human pd-l1, Human Antibody; MSB 0010718C; MSB0010718C	PD-1/PD-L1	Inflammation/Immunology Cancer
Avelumab is a fully human IgG1 anti-PD-L1 monoclonal antibody with potential antibody-dependent cell-mediated cytotoxicity.

HY-P99544

Tagitanlimab HBM-9167; KL-A167	PD-1/PD-L1	Cancer
Tagitanlimab (HBM-9167) is a *humanized anti-PD-L1* antibody (IgG1κ type). Tagitanlimab selectively blocks the interaction of PD-L1 and PD-1**. Tagitanlimab has the potential to be studied in recurrent or metastatic nasopharyngeal carcinoma (NPC) ^[1] .

HY-P99422

Adebrelimab SHR-1316	PD-1/PD-L1 Apoptosis	Cancer
Adebrelimab (SHR-1316) is a humanized IgG4 monoclonal *PD-L1* (PD-1/PD-L1) antibody. Adebrelimab has promising antitumor activity in solid tumors including extensive-stage small-cell lung cancer (SCLC) ^[1] .

HY-108730A

*Avelumab (anti-PD-L1)* 5+ Cited Publications	PD-1/PD-L1	Inflammation/Immunology Cancer
Avelumab (anti-PD-L1) is a fully human *IgG1* anti-PD-L1 monoclonal antibody with potential antibody-dependent cell-mediated cytotoxicity ^[1].

HY-P9972

Spartalizumab pdR001	PD-1/PD-L1	Cancer
Spartalizumab (PDR001) is a humanized immunoglobulin 4 monoclonal antibody that binds *PD-1* with subnanomolar activity and blocks interaction with PD-L1 and PD-L2. Spartalizumab can be used for the research of anaplastic thyroid carcinoma (ATC) ^[1].

HY-145771

*PD-1/PD-L1-IN-20*	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-20 (Example 21) is a small-molecule inhibitor of the PD-1/PD-L1 protein-protein interaction. PD-1/PD-L1-IN-20 blocks PD-1/PD-L1 with the IC₅₀ of 5.29 nM. PD-1/PD-L1-IN-20 can be used for the research of cancers, infectious diseases and autoimmune diseases ^[1].

HY-P99475

Betifisolimab MSB-2311	PD-1/PD-L1	Cancer
Betifisolimab (MSB-2311) is a humanized monoclonal antibody directed against the immunosuppressive ligand PD-L1. Betifisolimab has the potential for advanced solid tumors and hematological malignancies research ^[1].

HY-P99048

Sintilimab IBI308	PD-1/PD-L1	Inflammation/Immunology Cancer
Sintilimab (IBI308) is a fully human IgG4 monoclonal antibody that binds to *PD-1, thereby blocking the interaction of PD-1* with its ligands (PD-L1 and PL-L2) and consequently helping to restore the endogenous antitumour T-cell response. Sintilimab can be used for the research of classical Hodgkin's lymphoma, non-small cell lung cancer and oesophageal cancer ^[1].

HY-P99613

Favezelimab MK-4280	LAG-3	Cancer
Favezelimab (MK-4280) is a humanized anti-LAG-3 monoclonal antibody that blocks the interaction between LAG-3 and its ligand MHC class II. Favezelimab has the potential for colorectal cancer (CRC) research combined with the PD-L1 inhibitor Pembrolizumab (HY-P9902) ^[1] .

HY-P99115

Envafolimab ASC 22; KN 035	PD-1/PD-L1	Cancer
Envafolimab (ASC 22; KN 035) is a recombinant protein of a humanized single-domain anti- *PD-L1* antibody. Envafolimab is created by a fusion of the of anti-PD-L1 domain with Fc fragment of human IgG1 antibody. Envafolimab blocks interaction between PD-L1 and PD-1 with an IC₅₀ value of 5.25 nM. Envafolimab has the potential for the research of solid tumors ^[1] .

HY-P99723

Manelimab

BCD-135
PD-1/PD-L1 Cancer

Manelimab is a monoclonal antibody that inhibits programmed death-ligand 1 (PD-L1) ^[1].

HY-P9902A

Pembrolizumab (anti-PD-1) 2 Publications Verification	PD-1/PD-L1	Cancer
Pembrolizumab (anti-PD-1) is a humanized IgG4 antibody and *PD-1* inhibitor. Pembrolizumab produces *PD-1* blockade, preventing PD-L1 and PD-L2 from connecting to *PD-1. This avoids the uncontrolled regulation of T cells on cells that normally express PD-1* ^[1] .

HY-P990114

*Anti-Canine PD-L1/B7-H1 Antibody (JC071)*	Inhibitory Antibodies	Others
Anti-Canine PD-L1/B7-H1 Antibody (JC071) is a mouse-derived IgG1, κ type antibody inhibitor, targeting to canine PD-L1/B7-H1.

HY-P99799

Pacmilimab

CX-072
PD-1/PD-L1 Cancer

Pacmilimab (CX-072) is a potent PD-L1 inhibitor. Pacmilimab shows antitumor activity ^[1].

HY-P9919

Durvalumab 5 Publications Verification MEDI 4736	PD-1/PD-L1	Cancer
Durvalumab (MEDI 4736) is an human anti-PD-L1 monoclonal antibody ^[1]. Durvalumab (MEDI4736) completely blocks the binding of *PD-L1* to both *PD-1* and CD80, with IC₅₀s of 0.1 and 0.04 nM, respectively .

HY-P9904

Atezolizumab Maximum Cited Publications 19 Publications Verification MpdL3280A	PD-1/PD-L1 Apoptosis Autophagy	Cancer
Atezolizumab (MPDL3280A) is a selective humanized monoclonal IgG1 antibody against programmed death ligand 1 (PD-L1), used for cancer research.

HY-P99641

Gilvetmab

PD-1/PD-L1 Cancer

Gilvetmab is a potent caninized antiPD-1 monoclonal antibody. gilvetmab blocks the interaction between PD-1 and its ligand PDL-1 ^[1].

HY-P99610

Ezabenlimab BI-754091	PD-1/PD-L1	Cancer
Ezabenlimab (BI-754091) is an anti-PD-1 mAb with binding constant K_d value of 6 nM (CHO cells). Ezabenlimab blocks the interaction of *PD-1* with *PD-L1* and *PD-L2*. Ezabenlimab increases interferon-γ secretion in T cells, and inhibits tumor growth in vivo ^[1].

HY-P9971

Camrelizumab 1 Publications Verification SHR-1210	PD-1/PD-L1	Cancer
Camrelizumab (SHR-1210) is a potent humanied high-affinity IgG4-κ monoclonal antibody (mAb) to *PD-1. Camrelizumab binds PD-1* at a high affinity of 3 nM and inhibits the binding interaction of PD-1 and PD-L1 with an IC₅₀ of 0.70 nM. Camrelizumab acts as anti-PD-1/PD-L1 agent and can be used for cancer research, including NSCLC, ESCC, Hodgkin lymphoma, and advanced HCC et,al ^[1] .

HY-P99145A

*Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2™-CP168)*	Inhibitory Antibodies	Others
Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2?-CP168) is a mouse-derived IgG1, κ type antibody inhibitor, targeting to mouse PD-L1/B7-H1.

HY-P99345

Dostarlimab TSR-042	PD-1/PD-L1	Cancer
Dostarlimab (TSR-042) is a humanized anti-PD-1 monoclonal antibody. Dostarlimab binds with high affinity to human PD-1 and competitively inhibits its interaction with its ligands, PD-L1 and PD-L2, with IC₅₀s of 1.8 and 1.5 nM, respectively ^[1].

HY-P99499

Cetrelimab JNJ 63723283; JNJ 3283	PD-1/PD-L1 Interleukin Related TNF Receptor	Cancer
Cetrelimab (JNJ 63723283; JNJ 3283) is a human IgG4κ mAb targeting *PD-1. Cetrelimab binds PD-1* (K_d=1.72 nM, HEK293) to block the interaction of *PD-1* with *PD-L1* and *PD-L2* (IC₅₀s=111.7 ng/mL and 138.6 ng/mL, respectively). Cetrelimab stimulates peripheral T cells, increases IFN-γ, IL-2, TNF-α level and inhibits tumor growth in vivo ^[1].

HY-P990171

*Anti-Mouse PD-L1/B7-H1 (LALA-PG) Antibody (10F.9G2™-CP154)*	Inhibitory Antibodies	Others
Anti-Mouse PD-L1/B7-H1 (LALA-PG) Antibody (10F.9G2?-CP154) is a mouse-derived IgG2a, κ type antibody inhibitor, targeting to mouse PD-L1/B7-H1.

HY-P99419

Acasunlimab GEN1046	PD-1/PD-L1	Cancer
Acasunlimab (GEN1046) is a bispecific antibody (bsAb) targeting *PD-L1* and *4-1BB. Acasunlimab enhances T-cell and NK-cell function through conditional 4-1BB stimulation while constitutively blocking the PD-1/PD-L1* inhibitory axis. Acasunlimab can be used in research of cancer ^[1] .

HY-P990172

*Anti-Mouse PD-L1/B7-H1 (D265A) Antibody (10F.9G2™-CP001)*	Inhibitory Antibodies	Others
Anti-Mouse PD-L1/B7-H1 (D265A) Antibody (10F.9G2?-CP001) is a mouse-derived IgG1, κ type antibody inhibitor, targeting to mouse PD-L1/B7-H1.

HY-P99114

Sugemalimab	PD-1/PD-L1	Cancer
Sugemalimab is a fully human, full length, anti-programmed death ligand 1 (PD-L1) immunoglobulin G4 (IgG4) monoclonal antibody (mAb). Sugemalimab shows anticancer activities and can be used for non-small cell lung cancer research ^[1].

HY-P99109

Zimberelimab GLS-010; AB-122; WBP-3055	PD-1/PD-L1	Cancer
Zimberelimab (GLS-010) is a fully human IgG4 anti-PD-1 monoclonal antibody with an EC₅₀ of 210 pM for human PD-1. Zimberelimab effectively blocks the binding of PD-L1 and PD-L2 to cell-surface PD-1 in CHO-S cells, with IC₅₀ values of 580 pM and 670 pM, respectively. Zimberelimab shows antitumor activities, and can be used for various cancers research, including cervical cancer, non-small cell lung cancer and classical Hodgkin’s lymphoma ^[1] .

HY-P9986

Tiragolumab	Inhibitory Antibodies	Inflammation/Immunology Cancer
Tiragolumab is an immune checkpoint inhibitor binding to T-cell immunoglobulin and ITIM domain (TIGIT). Tiragolumab, alone or in combination with the PD-L1 inhibitor Atezolizumab (HY-P9904), may be effective against multiple solid malignancies-most notably non-small cell lung cancer (NSCLC) ^[1] .

HY-P99963

Sudubrilimab HS636	PD-1/PD-L1	Cancer
Sudubrilimab (HS636) is an Ig G1-kappa monoclonal antibody against *PDL1. Sudubrilimab is fused at the C terminus of the heavy chain to a TGF-β1 receptor Ⅱ ectodomain (TGFBR2-ECD), and which can sequester the PD-1/PD-L1* pathway and TGF-β bioactivity in the immunosuppressive tumor microenvironment ^[1].

HY-P990088

Sotiburafusp alfa	VEGFR PD-1/PD-L1	Cardiovascular Disease
Sotiburafusp alfa is a bispecific fusion protein, which is a humanized *VEGFR-1* extracellular domain fragment (129-228, 1-100 in the current sequence) fused via the peptide linker ¹⁰¹GGSGGSGGSGGSGGS ¹¹⁵ to the N-terminus of the heavy chain (116-564) of a humanized IgG1-kappa anti-human *PD-L1* heavy chain variant L352>A, L353>A. Sotiburafusp alfa is also an angiogenesis inhibitor ^[1].

HY-P990014

Danburstotug IMC-001; STI-3031	PD-1/PD-L1	Inflammation/Immunology Cancer
Danburstotug (IMC-001) is an IgG1-lambda anti-CD274 (PDL1, B7 homologue 1, B7H1) human monoclonal antibody. Danburstotug also is immunostimulant and antineoplastic ^[1].

HY-P99457

Balstilimab

AGEN2034
PD-1/PD-L1 Inflammation/Immunology

Balstilimab (AGEN2034) is a fully human monoclonal IgG4 antibody against PD-1 .
HY-P99106

Acrixolimab

PD-1/PD-L1 Cancer

Acrixolimab a humanized IgG4-κ antibody, targeting to PD-1 .
HY-P9997

Rosnilimab

ANB030
PD-1/PD-L1 Cancer

Rosnilimab is a humanized IgG1-κ antibody targeting to PD-1 .
HY-P99144

Anti-Mouse PD-1 Antibody (RMP1-14)

1 Publications Verification

PD-1/PD-L1 Inflammation/Immunology

Anti-Mouse PD-1 Antibody is an anti-mouse PD-1 IgG1 antibody inhibitor.
HY-P99679

Izuralimab

PD-1/PD-L1 Inflammation/Immunology Cancer

Izuralimab is a bispecific IgG1 antibody targeting inducible T-cell costimulator (ICOS/CD278) and PD-1 ^[1].
HY-P99449

Atorolimumab

P3x22914G4
PD-1/PD-L1 Inflammation/Immunology

Atorolimumab (P3x22914G4) is a monoclonal antibody used for immunotherapies targeting programmed death-1 (PD-1) .

HY-P99639

Geptanolimab APL-501; CBT-501; GB-226	PD-1/PD-L1	Cancer
Geptanolimab (CBT-501) is a humanized IgG4k monoclonal antibody against programmed death-1 (PD-1). Siplizumab inhibits the binding of PD-L1/L2 to PD-1 through a competitive action. Siplizumab can be used in research of cancer ^[1].

HY-P99203

Cemiplimab	PD-1/PD-L1	Cancer
Cemiplimab (Anti-Human PD-1) is a high-affinity programmed death receptor-1 (PD-1) monoclonal IgG4 antibody that blocks PD-1/PD-L1-mediated T-cell suppression. Cemiplimab is commonly used in squamous cell skin cancer research ^[1] .

HY-P99895

Rulonilimab	PD-1/PD-L1	Inflammation/Immunology Cancer
Rulonilimab is a human IgG1 monoclonal antibody against *PD-1* that targets, binds and inhibits PD-1 and its downstream signalling pathways with potential immune checkpoint inhibition and anti-tumour activity ^[1].

HY-P9978

Toripalimab	PD-1/PD-L1	Cancer
Toripalimab is the first domestic anti-tumor *PD-1* antibody in China. Toripalimab is a selective, recombinant, humanized monoclonal antibody against PD-1. Toripalimab is able to bind to PD-1 and block the interaction with its ligands. Toripalimab has exhibited primary anti-tumor effects in tumors such as melanoma, lung cancer, digestive tract tumors, hepatobiliary and pancreatic tumors, neuroendocrine neoplasms, nasopharyngeal carcinoma and urothelial carcinoma ^[1].

HY-P99166

Vudalimab	PD-1/PD-L1 CTLA-4	Inflammation/Immunology
Vudalimab is a potent dual *PD-1* and CTLA-4 inhibitor as a fully humanized bispecific monoclonal antibody. Vudalimab targets immune checkpoint receptors PD-1 and CTLA-4 and promotes tumor-selective T-cell activation ^[1].

HY-P99618

Fidasimtamab IBI-315; BH2950	EGFR PD-1/PD-L1	Inflammation/Immunology Cancer
Fidasimtamab (IBI-315; BH2950) is a recombinant human IgG1 bispecific antibody that targets, binds and inhibits both HER2 and *PD-1* and their downstream signalling pathways, and links PD-1 expressing T cells to HER2 expressing tumour cells. Fidasimtamab has potential immunosuppressive and antitumor activity ^[1].

HY-P99887

Pimivalimab

JTX-4014
PD-1/PD-L1 Cancer

Pimivalimab (JTX-4014) is a PD-1 inhibitor. Pimivalimab can be used for the research of solid tumor ^[1].
HY-P99957

Zeluvalimab

AMG-404
PD-1/PD-L1 Cancer

Zeluvalimab (AMG-404) is a monoclonal antibody targeting the PD-1 receptor that can be used for the research of cancer ^[1].

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0242

Fraxinellone 1 Publications Verification	Classification of Application Fields Terpenoids Dictamnus dasycarpus Turcz. Sesquiterpenes Source classification Rutaceae Plants Inflammation/Immunology Disease Research Fields	PD-1/PD-L1 HIF/HIF Prolyl-Hydroxylase STAT
Fraxinellone is isolated from the root bark of the Rutaceae plant, Dictamnus dasycarpus. Fraxinellone is a *PD-L1* inhibitor and inhibits *HIF-1α* protein synthesis without affecting HIF-1α protein degradation. Fraxinellone has the potential to be a valuable candidate for cancer treatment by targeting PD-L1 ^[1].

HY-N0596

Panaxadiol 20(R)-Panaxadiol	Panax ginseng C. A. Meyer Triterpenes Structural Classification Classification of Application Fields Terpenoids Source classification Plants Disease Research Fields Araliaceae Cancer	PD-1/PD-L1 HIF/HIF Prolyl-Hydroxylase STAT
Panaxadiol (20(R)-Panaxadiol) is an orally active *HIF-1α/STAT3* inhibitor. Panaxadiol can suppress HIF-1α and STAT3 then lead to downregulation of programmed cell death-ligand 1 (PD-L1) expression. Panaxadiol shows anticancer, cardioprotective, anti-arrhythmic, and antioxidative activities ^[1] .

HY-N12687

Benzosceptrin C	Structural Classification Alkaloids Pyrrole Alkaloids Marine natural products Source classification	PD-1/PD-L1 Apoptosis
Benzosceptrin C is an inhibitor for *PD-L1, which promotes programmed cell death ligand (PD-L1*) degradation in a lysosomal pathway, enhances the cytotoxicity of T-cells and exhibits antitumor activity ^[1].

HY-N12537

*PD-1/PD-L1-IN-38*	Structural Classification Ketones, Aldehydes, Acids Labiatae Source classification Samanea saman (Jacq.) Merr. Plants	PD-1/PD-L1
PD-1/ PD-L1-in-38 is a *PD-1/PD-L1* inhibitor, which can inhibit the proliferation of tumor cells, promote the secretion of INF-γ by CD8 ⁺ T cells, and inhibit the ability of PD-1/PD-L1 signal transduction. PD-1/PD-L1-IN-38 has antitumor activity ^[1].

HY-N12537A

*(2R,3S)-PD-1/PD-L1-IN-38*	Structural Classification Ketones, Aldehydes, Acids Labiatae Source classification Samanea saman (Jacq.) Merr. Plants	Aryl Hydrocarbon Receptor PD-1/PD-L1
(2R,3S)-PD-1/PD-L1-IN-38 (Compound (±)-13e) is an orally active Ah receptor (AhR) antagonist with in vivo and in vitro anticancer activity. (2R,3S)-PD-1/PD-L1-IN-38 promotes the secretion of INF-γ by CD8 ⁺T cells and inhibits the signal transduction of PD-1/PD-L1 ^[1].

HY-N0460

1-Caffeoylquinic acid	Phyllodium pulchellum (L.) Desv. Classification of Application Fields Source classification Phenols Polyphenols Plants Compositae Disease Research Fields Cancer	NF-κB
1-Caffeoylquinic acid is an effective NF-κB inhibitor, shows significant binding affinity to the RH domain of p105 with K_i of 0.002 μM and binding energy of 1.50 Kcal/mol ^[1]. 1-Caffeoylquinic acid has anti-oxidative stress ability . 1-Caffeoylquinic acid inhibits *PD-1/PD-L1* interact .

Recombinant Proteins Recommended:

PD-L1

Species:	Human (8) Rhesus Macaque (2) Rat (3) Mouse (5) Cynomolgus (2) Canine (2)
Tag:	His (11) Tag Free (1) Avi (2) Fc (10) Flag (1)
Source:	HEK293 (21) CHO (1)

Cat. No.	Compare	Product Name	Species	Source

HY-P73361

	PD-L1 Protein, Human (HEK293) 4 Publications Verification Programmed cell death 1 ligand 1; pd-l1; B7-H1; CD274; pdl1	Human	HEK293
	The PD-L1 protein critically regulates immune tolerance by acting as a ligand for PDCD1/PD-1, regulating T cell activation threshold, and limiting effector responses. It may act as a costimulatory molecule for IL10-producing T cell subsets. PD-L1 Protein, Human (HEK293) is the recombinant human-derived PD-L1 protein, expressed by HEK293 , with tag free. The total length of PD-L1 Protein, Human (HEK293) is 220 a.a., with molecular weight of ~36 kDa.

HY-P73364

	PD-L1 Protein, Rat (HEK293, Fc) Programmed cell death 1 ligand 1; pd-l1; B7-H1; CD274; pdl1	Rat	HEK293
	PD-L1 (Programmed death-ligand 1) critically regulates T cell proliferation and migration, acting as a biomarker for periodontitis and pre-eclampsia. CD274 is its human ortholog. Biased expression in the thymus (RPKM 102.9), spleen (RPKM 58.3), and other tissues emphasizes PD-L1's centrality in immune regulation across diverse physiological and pathological conditions. PD-L1 Protein, Rat (HEK293, Fc) is the recombinant rat-derived PD-L1 protein, expressed by HEK293 , with C-hFc labeled tag. The total length of PD-L1 Protein, Rat (HEK293, Fc) is 221 a.a., with molecular weight of ~63 kDa.

HY-P73365

	PD-L1 Protein, Rat (HEK293, His) Programmed cell death 1 ligand 1; pd-l1; B7-H1; CD274; pdl1	Rat	HEK293
	PD-L1 (Programmed death-ligand 1) critically regulates T cell proliferation and migration, acting as a biomarker for periodontitis and pre-eclampsia. CD274 is its human ortholog. Biased expression in the thymus (RPKM 102.9), spleen (RPKM 58.3), and other tissues emphasizes PD-L1's centrality in immune regulation across diverse physiological and pathological conditions. PD-L1 Protein, Rat (HEK293, His) is the recombinant rat-derived PD-L1 protein, expressed by HEK293 , with C-10*His labeled tag. The total length of PD-L1 Protein, Rat (HEK293, His) is 221 a.a., with molecular weight of ~41.79 kDa.

HY-P73717

	PD-L1 Protein, Canine (HEK293, Fc) Programmed cell death 1 ligand 1; pd-l1; B7-H1; CD274; pdl1	Canine	HEK293
	PD-L1 Protein, Canine (HEK293, Fc) is a trans-membrane protein that is considered to be a co-inhibitory factor of the immune response. The amino acid sequence of PD-L1 is encoded by 7 exons, which form a protein of ~40 kDa. PD-L1 is a type I transmembrane protein, is part of the immunoglobulin (Ig) superfamily and is composed of IgV-like and IgC-like extracellular domains, a hydrophobic transmembrane domain and a short cytoplasmic tail composed of 30 amino acids. PD-L1 can combine with PD-1 to reduce the proliferation of PD-1 positive cells, inhibit their cytokine secretion and induce apoptosis. PD-L1 also plays an important role in various malignancies where it can attenuate the host immune response to tumor cells. PD-L1 Protein, Canine (HEK293, Fc) is the recombinant canine-derived PD-L1 protein, expressed by HEK293 , with C-hFc labeled tag. The total length of PD-L1 Protein, Canine (HEK293, Fc) is 218 a.a., with molecular weight of ~70-80 & 140-160 kDa, respectively.

HY-P73716

	PD-L1 Protein, Mouse (HEK293, His-Fc) Programmed cell death 1 ligand 1; pd-l1; B7-H1; CD274; pdl1	Mouse	HEK293
	PD-L1 protein serves as a ligand for the inhibitory receptor PDCD1/PD-1 and is critical for maintaining immune tolerance. This interaction modulates T cell activation, limits effector responses and may stimulate IL10-producing T cell subsets. PD-L1 Protein, Mouse (HEK293, His-Fc) is the recombinant mouse-derived PD-L1 protein, expressed by HEK293 , with C-hFc, C-His labeled tag. The total length of PD-L1 Protein, Mouse (HEK293, His-Fc) is 238 a.a., with molecular weight of 64-90 kDa.

HY-P77347

	PD-L1 Protein, Cynomolgus/Rhesus Macaque (HEK293, His) Programmed cell death 1 ligand 1; pd-l1; B7-H1; CD274; pdl1	Rhesus Macaque	HEK293
	The PD-L1 protein critically regulates immune tolerance by acting as a ligand for PDCD1/PD-1, regulating T cell activation threshold, and limiting effector responses. It may act as a costimulatory molecule for IL10-producing T cell subsets. PD-L1 Protein, Cynomolgus/Rhesus Macaque (HEK293, His) is the recombinant Rhesus Macaque-derived PD-L1 protein, expressed by HEK293 , with C-His labeled tag. The total length of PD-L1 Protein, Cynomolgus/Rhesus Macaque (HEK293, His) is 239 a.a., with molecular weight of ~37.7 kDa.

HY-P73363

	PD-L1 Protein, Mouse (239a.a, HEK293, Fc) Programmed cell death 1 ligand 1; pd-l1; B7-H1; CD274; pdl1	Mouse	HEK293
	PD-L1 protein serves as a ligand for the inhibitory receptor PDCD1/PD-1 and is critical for maintaining immune tolerance. This interaction modulates T cell activation, limits effector responses and may stimulate IL10-producing T cell subsets. PD-L1 Protein, Mouse (239a.a, HEK293, Fc) is the recombinant mouse-derived PD-L1 protein, expressed by HEK293 , with C-hFc labeled tag. The total length of PD-L1 Protein, Mouse (239a.a, HEK293, Fc) is 239 a.a., with molecular weight of ~51.6 kDa.

HY-P77348

	PD-L1 Protein, Cynomolgus/Rhesus Macaque (Biotinylated, HEK293, His) Programmed cell death 1 ligand 1; pd-l1; B7-H1; CD274; pdl1	Rhesus Macaque	HEK293
	The PD-L1 protein critically regulates immune tolerance by acting as a ligand for PDCD1/PD-1, regulating T cell activation threshold, and limiting effector responses. It may act as a costimulatory molecule for IL10-producing T cell subsets. PD-L1 Protein, Cynomolgus/Rhesus Macaque (Biotinylated, HEK293, His) is the recombinant Rhesus Macaque-derived PD-L1 protein, expressed by HEK293 , with C-His labeled tag. The total length of PD-L1 Protein, Cynomolgus/Rhesus Macaque (Biotinylated, HEK293, His) is 239 a.a., with molecular weight of ~26.7 KDa.

HY-P78633

	PD-L1 Protein, Canine (HEK293, His) pd-l1; CD274; B7-H1; pdCD1l1; pdCD1LG1	Canine	HEK293
	The PD-L1 protein critically regulates immune tolerance by acting as a ligand for PDCD1/PD-1, regulating T cell activation threshold, and limiting effector responses. It may act as a costimulatory molecule for IL10-producing T cell subsets. PD-L1 Protein, Canine (HEK293, His) is the recombinant canine-derived PD-L1 protein, expressed by HEK293 , with C-His labeled tag. The total length of PD-L1 Protein, Canine (HEK293, His) is 218 a.a., with molecular weight (glycosylation form) of 50 & 100 kDa, respectively.

HY-P70657

	PD-L1 Protein, Human (HEK293, mFc) Programmed Cell Death 1 Ligand 1; pd-l1; pdCD1 Ligand 1; Programmed Death Ligand 1; B7 Homolog 1; B7-H1; CD274; B7H1; pdCD1l1; pdCD1LG1; pdl1	Human	HEK293
	The PD-L1 protein critically regulates immune tolerance by acting as a ligand for PDCD1/PD-1, regulating T cell activation threshold, and limiting effector responses. It may act as a costimulatory molecule for IL10-producing T cell subsets. PD-L1 Protein, Human (HEK293, mFc) is the recombinant human-derived PD-L1 protein, expressed by HEK293 , with C-mFc labeled tag. The total length of PD-L1 Protein, Human (HEK293, mFc) is 221 a.a., with molecular weight of 59-89 kDa.

HY-P70663

	PD-L1 Protein, Human (HEK293, Flag) Programmed Cell Death 1 Ligand 1; pd-l1; pdCD1 Ligand 1; Programmed Death Ligand 1; B7 Homolog 1; B7-H1; CD274; B7H1; pdCD1l1; pdCD1LG1; pdl1	Human	HEK293
	The PD-L1 protein critically regulates immune tolerance by acting as a ligand for PDCD1/PD-1, regulating T cell activation threshold, and limiting effector responses. It may act as a costimulatory molecule for IL10-producing T cell subsets. PD-L1 Protein, Human (HEK293, Flag) is the recombinant human-derived PD-L1 protein, expressed by HEK293 , with C-Flag labeled tag. The total length of PD-L1 Protein, Human (HEK293, Flag) is 221 a.a., with molecular weight of 35-40 kDa.

HY-P70672

	PD-L1 Protein, Human (221a.a, HEK293, Fc) Programmed Cell Death 1 Ligand 1; pd-l1; pdCD1 Ligand 1; Programmed Death Ligand 1; B7 Homolog 1; B7-H1; CD274; B7H1; pdCD1l1; pdCD1LG1; pdl1	Human	HEK293
	The PD-L1 protein critically regulates immune tolerance by acting as a ligand for PDCD1/PD-1, regulating T cell activation threshold, and limiting effector responses. It may act as a costimulatory molecule for IL10-producing T cell subsets. PD-L1 Protein, Human (221a.a, HEK293, Fc) is the recombinant human-derived PD-L1 protein, expressed by HEK293 , with C-hFc labeled tag. The total length of PD-L1 Protein, Human (221a.a, HEK293, Fc) is 221 a.a., with molecular weight of 70-80 kDa.

HY-P70721

	PD-L1 Protein, Human (Biotinylated, HEK293, Fc-Avi) Programmed Cell Death 1 Ligand 1; pd-l1; pdCD1 ligand 1; Programmed death ligand 1; B7 homolog 1; B7-H1; CD274; B7H1; pdCD1l1; pdCD1LG1; pdl1	Human	HEK293
	The PD-L1 protein critically regulates immune tolerance by acting as a ligand for PDCD1/PD-1, regulating T cell activation threshold, and limiting effector responses. It may act as a costimulatory molecule for IL10-producing T cell subsets. PD-L1 Protein, Human (Biotinylated, HEK293, Fc-Avi) is the recombinant human-derived PD-L1 protein, expressed by HEK293 , with C-Avi, C-hFc labeled tag. The total length of PD-L1 Protein, Human (Biotinylated, HEK293, Fc-Avi) is 221 a.a., with molecular weight of 70-95 kDa.

HY-P77819

	PD-L1 Protein, Mouse (Biotinylated, HEK293, His) CD274; pdl1; pd-l1; pd-l1B7 homolog 1; B7-H; B7H1; B7-H1; pdCD1l1; pdCD1LG1	Mouse	HEK293
	PD-L1 protein serves as a ligand for the inhibitory receptor PDCD1/PD-1 and is critical for maintaining immune tolerance. This interaction modulates T cell activation, limits effector responses and may stimulate IL10-producing T cell subsets. PD-L1 Protein, Mouse (Biotinylated, HEK293, His) is the recombinant mouse-derived PD-L1 protein, expressed by HEK293 , with C-His labeled tag. The total length of PD-L1 Protein, Mouse (Biotinylated, HEK293, His) is 220 a.a., with molecular weight of 45-60 kDa.

HY-P78192

	PD-L1 Protein, Human (Biotinylated, HEK293, His-Avi) CD274; pdl1; pd-l1; pd-l1B7 homolog 1; B7-H; B7H1; B7-H1; pdCD1l1; pdCD1LG1	Human	HEK293
	The PD-L1 protein critically regulates immune tolerance by acting as a ligand for PDCD1/PD-1, regulating T cell activation threshold, and limiting effector responses. It may act as a costimulatory molecule for IL10-producing T cell subsets. PD-L1 Protein, Human (Biotinylated, HEK293, His-Avi) is the recombinant human-derived PD-L1 protein, expressed by HEK293 , with C-Avi, C-His labeled tag. The total length of PD-L1 Protein, Human (Biotinylated, HEK293, His-Avi) is 220 a.a., with molecular weight of 35-45 kDa.

HY-P70564

	PD-L1 Protein, Cynomolgus (HEK293, His) B7-H; B7H1; B7-H1; pdCD1l1; CD274 molecule; CD274; pdCD1l1; pdCD1LG1; pdl1; pd-l1; pd-l1B7 homolog 1; pdl1pdCD1 ligand 1; programmed cell death 1 ligand 1; Programmed death ligand 1	Cynomolgus	HEK293
	CD274 molecule, also known as programmed death ligand 1 (PD-L1), binds to the checkpoint suppressor molecule PD-1 to inhibit TCR-mediated IL-2 production and T cell proliferation signaling. PD-L1 is involved in the PI3K/JAK/STAT signaling pathway to promote tumor occurrence. PD-L1 Protein, Cynomolgus (HEK293, His) is the recombinant cynomolgus-derived PD-L1 protein, expressed by HEK293 , with C-6*His labeled tag. The total length of PD-L1 Protein, Cynomolgus (HEK293, His) is 221 a.a., with molecular weight of 32-40 kDa.

HY-P71008

	PD-L1 Protein, Cynomolgus (HEK293, Fc) B7-H; B7H1; B7-H1; B7H1pdCD1l1; CD274 antigenMGC142294; CD274 molecule; CD274; pdCD1l1; pdCD1LG1; pdl1; pd-l1; pd-l1B7 homolog 1; pdl1pdCD1 ligand 1; programmed cell death 1 ligand 1; Programmed death ligand 1	Cynomolgus	HEK293
	CD274 molecule, also known as programmed death ligand 1 (PD-L1), binds to the checkpoint suppressor molecule PD-1 to inhibit TCR-mediated IL-2 production and T cell proliferation signaling. PD-L1 is involved in the PI3K/JAK/STAT signaling pathway to promote tumor occurrence. PD-L1 Protein, Cynomolgus (HEK293, Fc) is the recombinant cynomolgus-derived PD-L1 protein, expressed by HEK293 , with C-hFc labeled tag. The total length of PD-L1 Protein, Cynomolgus (HEK293, Fc) is 221 a.a., with molecular weight of ~73.0 kDa.

HY-P70814

	PD-L1 Protein, Rat (221a.a, HEK293, His) B7-H; B7H1; B7-H1; B7H1pdCD1l1; CD274 antigenMGC142294; CD274 molecule; CD274; pdCD1l1; pdCD1LG1; pdl1; pd-l1; pd-l1B7 homolog 1; pdl1pdCD1 ligand 1; programmed cell death 1 ligand 1; Programmed death ligand 1	Rat	HEK293
	PD-L1 Protein is a type I transmembrane protein that belongs to the immunoglobulin (Ig) superfamily. PD-L1 can interact with PD-1, and PD-1/PD-L1 axis is responsible for T cell activation, proliferation, and cytotoxic secretion in cancer, and regulates anti-tumor immune responses. PD-L1 plays a major role in suppressing the adaptive arm of immune systems. PD-L1 Protein, Rat (221a.a, HEK293, His) is the recombinant rat-derived PD-L1 protein, expressed by HEK293 , with C-6*His labeled tag. The total length of PD-L1 Protein, Rat (221a.a, HEK293, His) is 221 a.a., with molecular weight of 40-60 kDa.

HY-P70632

	PD-L1 Protein, Mouse (HEK293, His) Programmed cell death 1 ligand 1Cd274; programmed cell death 1 ligand 1; pd-l1; pdCD1 ligand 1; programmed death ligand 1; B7 homolog 1; B7-H1; CD274	Mouse	HEK293
	PD-L1 protein serves as a ligand for the inhibitory receptor PDCD1/PD-1 and is critical for maintaining immune tolerance. This interaction modulates T cell activation, limits effector responses and may stimulate IL10-producing T cell subsets. PD-L1 Protein, Mouse (HEK293, His) is the recombinant mouse-derived PD-L1 protein, expressed by HEK293 , with C-6*His labeled tag. The total length of PD-L1 Protein, Mouse (HEK293, His) is 220 a.a., with molecular weight of 38-58 kDa.

HY-P70633

	PD-L1 Protein, Mouse (220a.a, HEK293, Fc) Programmed cell death 1 ligand 1Cd274; programmed cell death 1 ligand 1; pd-l1; pdCD1 ligand 1; programmed death ligand 1; B7 homolog 1; B7-H1; CD274;	Mouse	HEK293
	PD-L1 protein serves as a ligand for the inhibitory receptor PDCD1/PD-1 and is critical for maintaining immune tolerance. This interaction modulates T cell activation, limits effector responses and may stimulate IL10-producing T cell subsets. PD-L1 Protein, Mouse (220a.a, HEK293, Fc) is the recombinant mouse-derived PD-L1 protein, expressed by HEK293 , with C-hFc labeled tag. The total length of PD-L1 Protein, Mouse (220a.a, HEK293, Fc) is 220 a.a., with molecular weight of 66-90 kDa.

HY-P7397

	PD-L1 Protein, Human (CHO, Fc) rHupd-l1, Fc Chimera; Programmed death ligand 1; CD274; B7-H1	Human	CHO
	PD-L1 Protein, Human (CHO, Fc) play a major role in suppressing the adaptive arm of immune system during particular events such as pregnancy, tissue allografts, autoimmune disease and other disease states such as hepatitis.

HY-P7398

	PD-L1 Protein, Human (HEK293, His) rHupd-l1, His; Programmed death ligand 1; CD274; B7-H1	Human	HEK293
	PD-L1 Protein, Human (HEK293, His) play a major role in suppressing the adaptive arm of immune system during particular events such as pregnancy, tissue allografts, autoimmune disease and other disease states such as hepatitis.

Cat. No.	Product Name	Chemical Structure

HY-132559S

PD-166285-d4

PD-166285-d₄ is the deuterium labeled PD-166285[1].

Cat. No.	Product Name	Application	Reactivity

HY-P80273

PD-L1 Antibody	WB, IHC-P	Human
PD-L1 Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 33 kDa, targeting to PD-L1. It can be used for WB,IHC-P assays with tag free, in the background of Human.

Cat. No.	Product Name		Classification

HY-162356

PD-L1-IN-4		Azide
PD-L1-IN-4 (Compound X18) is an orally active *PD-L1* inhibitor that exhibits remarkable inhibitory activity against the PD-1/PD-L1 interaction (IC₅₀ = 1.3 nM) and enhances PD-L1 inhibitory effect on T cells (EC₅₀ = 152.8 nM). PD-L1-IN-4 can be used for the research of cancer ^[1].


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inhibitors & Agonists

Screening Libraries

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Click Chemistry